Sign up to save your podcasts
Or
Share Press Release: Wegovy (Semaglutide) now approved for MASH
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Press Release: Wegovy (Semaglutide) now approved for MASH
Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.
In this episode of Skinfluenced: The Skin Podcast, we take a break from only skin diseases, and delve into our wellness side to take a look into some ground breaking research shaping the understanding and treatment of the newest GLP-1 indication: metabolic dysfunction–associated steatohepatitis (MASH). Join us as we dive into the groundbreaking developments surrounding semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, and its expanding therapeutic potential from upcoming FDA approvals to emerging pharmacologic strategies, this episode breaks down what these findings mean for providers, patients, and the future of disease management.
#Semaglutide #MASH #LiverDisease #GLP1agonist #Wegovy #LiverFibrosis #Steatohepatitis #MetabolicHealth #Obesity #Type2Diabetes #WeightLoss #Cardiometabolic #ClinicalTrials #FDAApproval #ESSENCEtrial #HeartFailure #HFpEF #ChronicKidneyDisease #NeurodegenerativeDiseases #AlzheimersDisease #ParkinsonsDisease #MASLD #NAFLD #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast
Link to Source(s):
FDA (2024): FDA Approves Treatment for Serious Liver Disease Known as MASH
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash
Journal of Hepatology (2020): A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement
https://www.sciencedirect.com/science/article/abs/pii/S0168827820302014
PubMed (2022): Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative Diseases: A Narrative Review
https://pubmed.ncbi.nlm.nih.gov/35650449/
PubMed (2023): Efficacy and Safety of Semaglutide in Non-Alcoholic Fatty Liver Disease
https://pubmed.ncbi.nlm.nih.gov/37899788/
PubMed (2024): Semaglutide Versus Placebo in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Pooled Analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Randomised Trials
https://pubmed.ncbi.nlm.nih.gov/39222642/
PubMed (2025): Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
https://pubmed.ncbi.nlm.nih.gov/40004240/
The New England Journal of Medicine (2023): Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
The New England Journal of Medicine (2025): Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
https://scholarindexing.com/uploads/files/8pu3_1ome6lcxkb.pdf
View all episodes
By Skinfluenced - The Skin PodcastDisclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.
In this episode of Skinfluenced: The Skin Podcast, we take a break from only skin diseases, and delve into our wellness side to take a look into some ground breaking research shaping the understanding and treatment of the newest GLP-1 indication: metabolic dysfunction–associated steatohepatitis (MASH). Join us as we dive into the groundbreaking developments surrounding semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, and its expanding therapeutic potential from upcoming FDA approvals to emerging pharmacologic strategies, this episode breaks down what these findings mean for providers, patients, and the future of disease management.
#Semaglutide #MASH #LiverDisease #GLP1agonist #Wegovy #LiverFibrosis #Steatohepatitis #MetabolicHealth #Obesity #Type2Diabetes #WeightLoss #Cardiometabolic #ClinicalTrials #FDAApproval #ESSENCEtrial #HeartFailure #HFpEF #ChronicKidneyDisease #NeurodegenerativeDiseases #AlzheimersDisease #ParkinsonsDisease #MASLD #NAFLD #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast
Link to Source(s):
FDA (2024): FDA Approves Treatment for Serious Liver Disease Known as MASH
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash
Journal of Hepatology (2020): A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement
https://www.sciencedirect.com/science/article/abs/pii/S0168827820302014
PubMed (2022): Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative Diseases: A Narrative Review
https://pubmed.ncbi.nlm.nih.gov/35650449/
PubMed (2023): Efficacy and Safety of Semaglutide in Non-Alcoholic Fatty Liver Disease
https://pubmed.ncbi.nlm.nih.gov/37899788/
PubMed (2024): Semaglutide Versus Placebo in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Pooled Analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Randomised Trials
https://pubmed.ncbi.nlm.nih.gov/39222642/
PubMed (2025): Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
https://pubmed.ncbi.nlm.nih.gov/40004240/
The New England Journal of Medicine (2023): Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
The New England Journal of Medicine (2025): Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
https://scholarindexing.com/uploads/files/8pu3_1ome6lcxkb.pdf